Insider · CIK 0001770821

Holsinger Leslie

Reports to the SEC for 1 company · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001770821

Forms 4 and 5

Insider transactions

17 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2022-06-06	IRLAIRulya Therapeutics Inc.F Tax Payment	EVP, Preclinical Development	FTax Payment	−10.9K sh	$2.86	−$31.2K	148,080
2022-03-03	IRLAIRulya Therapeutics Inc.A Award	EVP, Preclinical Development	AAward	+156K sh	—	—	159,000
2022-01-03	IRLAIRulya Therapeutics Inc. · Stock option (right to buy)A Award	EVP, Preclinical Development	AAward	+125K sh	—	—	125,000
2020-12-14	IRLAIRulya Therapeutics Inc. · Stock Option (Right to Buy)M Exercise/Conversion	EVP, Preclinical Development	MExercise/Conversion	−40K sh	—	—	66,794
2020-12-14	IRLAIRulya Therapeutics Inc.S Sale	EVP, Preclinical Development	SSale	−13.2K sh	$30.91	−$408K	14,325
2020-12-14	IRLAIRulya Therapeutics Inc.S Sale	EVP, Preclinical Development	SSale	−9,525 sh	$31.79	−$303K	1,800
2020-12-14	IRLAIRulya Therapeutics Inc.S Sale	EVP, Preclinical Development	SSale	−400 sh	$32.59	−$13K	4,400
2020-12-14	IRLAIRulya Therapeutics Inc.S Sale	EVP, Preclinical Development	SSale	−900 sh	$32.59	−$29.3K	3,500
2020-12-14	IRLAIRulya Therapeutics Inc.M Exercise/Conversion	EVP, Preclinical Development	MExercise/Conversion	+40K sh	$0.27	+$10.8K	43,500
2020-12-14	IRLAIRulya Therapeutics Inc.S Sale	EVP, Preclinical Development	SSale	−1,700 sh	$28.80	−$49K	41,800
2020-12-14	IRLAIRulya Therapeutics Inc.S Sale	EVP, Preclinical Development	SSale	−14.3K sh	$30.15	−$430K	27,525
2020-12-11	IRLAIRulya Therapeutics Inc. · Stock Option (Right to Buy)A Award	EVP, Preclinical Development	AAward	+100K sh	—	—	100,000
2020-12-11	IRLAIRulya Therapeutics Inc. · Stock Option (Right to Buy)A Award	EVP, Preclinical Development	AAward	+100K sh	—	—	100,000
2020-12-10	IRLAIRulya Therapeutics Inc.M Exercise/Conversion	EVP, Preclinical Development	MExercise/Conversion	+3,500 sh	$0.27	+$945	3,500
2020-12-10	IRLAIRulya Therapeutics Inc. · Stock Option (Right to Buy)M Exercise/Conversion	EVP, Preclinical Development	MExercise/Conversion	−3,500 sh	—	—	106,794
2020-05-14	IRLAIRulya Therapeutics Inc. · Stock Option (Right to Buy)A Award	EVP, Preclinical Development	AAward	+30K sh	—	—	30,000
2020-02-06	IRLAIRulya Therapeutics Inc. · Stock Option (Right to Buy)A Award	EVP, Preclinical Development	AAward	+100K sh	—	—	100,000

Recent filings

Accepted (ET)
Jun 84
Holsinger Leslie0001209191-22-035017
SEC(opens sec.gov)
Mar 44
Holsinger Leslie0001209191-22-016429
SEC(opens sec.gov)
Jan 54
Holsinger Leslie0001209191-22-001759
SEC(opens sec.gov)
Dec 154
Holsinger Leslie0001209191-20-063615
SEC(opens sec.gov)
Dec 144
Holsinger Leslie0001209191-20-063277
SEC(opens sec.gov)
May 184
Holsinger Leslie0001209191-20-030022
SEC(opens sec.gov)
Feb 104
Holsinger Leslie0001209191-20-008066
SEC(opens sec.gov)

Companies

IRulya Therapeutics Inc.EVP, Preclinical DevelopmentIRLA

Address

C/O CORTEXYME, INC. 269 EAST GRAND AVE.

SOUTH SAN FRANCISCO, CA, 94080